טוען...
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
CD137 (4-1BB) is a surface glycoprotein that belongs to the tumour necrosis factor receptor family (TNFRSF9). Its expression is induced on activation on a number of leucocyte types. Interestingly, for cancer immunotherapy, CD137 becomes expressed on primed T and natural killer (NK) cells, which on l...
שמור ב:
| הוצא לאור ב: | ESMO Open |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7333812/ https://ncbi.nlm.nih.gov/pubmed/32611557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000733 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|